Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study.
about
Pharmacological Inhibition of Monoacylglycerol O-Acyltransferase 2 Improves Hyperlipidemia, Obesity, and Diabetes by Change in Intestinal Fat UtilizationPostprandial Metabolism of Macronutrients and Cardiometabolic Risk: Recent Developments, Emerging Concepts, and Future Directions.Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure.Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndromeIdentification of a botanical inhibitor of intestinal diacylglyceride acyltransferase 1 activity via in vitro screening and a parallel, randomized, blinded, placebo-controlled clinical trial.Novel Agents for the Treatment of Type 2 Diabetes.Intestine-specific expression of MOGAT2 partially restores metabolic efficiency in Mogat2-deficient mice.The role of lipids in the pathogenesis and treatment of type 2 diabetes and associated co-morbidities.Demystifying the management of hypertriglyceridaemia.Chylomicronaemia--current diagnosis and future therapies.New perspectives on the development of antiobesity drugs.Peritumoral expression of adipokines and fatty acids in breast cancer.Identification and characterization of sebaceous gland atrophy-sparing DGAT1 inhibitors.Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety.Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.Pharmacological inhibition of DGAT1 induces sebaceous gland atrophy in mouse and dog skin while overt alopecia is restricted to the mouse.Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1.A Narrative Review of Potential Future Antidiabetic Drugs: Should We Expect More?
P2860
Q28550545-8854A0EB-7A73-4E05-9430-EE3438164DB1Q30362026-F4F8A753-4798-488E-B083-E863AF4B9EC1Q34396881-D62E43B4-F7E4-4965-AE87-BB8961C08D41Q35109548-D16EEA52-2C8C-4772-B8AA-CC08C1241718Q35738483-F49F2A93-4E3C-4503-B629-A3AE534F5982Q35910421-1B5EE094-ACB1-4CDC-AE69-ED3D638DF8A6Q36822585-AA629C2A-0058-43BB-ABB3-F5AE4CBF8C24Q37024780-3C3ACC9A-88F6-41C6-8751-94C035833554Q38141575-E799A4FB-CE53-4592-B8EA-FEFE0BF0F719Q38366873-B85094D4-D85E-41CF-A184-593682745183Q38397340-0AB97AE4-DAF1-411E-8419-2C1DE4A70F9AQ39347364-24D542D3-673C-43CF-8081-ACB8CA17ACEBQ41963944-FBBB10FD-6F10-4CE8-8265-0ABA09C0AD01Q42232469-EAA067BD-2326-47F0-BBFD-68780C77FCA4Q46680329-E7562CA9-69E2-4024-961C-525B02E6AC3DQ46853760-F3AE41A3-E1FA-49F7-B98C-6968861DB8A2Q49874392-D5D89654-5D85-4559-9FEB-083682D8ADBDQ52590826-C032BF56-E500-477D-836C-7326339077B9
P2860
Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-in-human single-dose study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@en
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@nl
type
label
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@en
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@nl
prefLabel
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@en
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@nl
P2093
P2860
P356
P1476
Proof of mechanism for the DGA ...... me-in-human single-dose study.
@en
P2093
C Karlsson
J W Eriksson
M Knutsson
P2860
P304
P356
10.1111/DOM.12002
P577
2012-09-30T00:00:00Z